Biostem Technologies Stock

Biostem Technologies EBIT

The EBIT of Biostem Technologies (BSEM) as of Jul 26, 2026 is 31.20 M USD. In the previous year, EBIT was -7.78 M USD — a change of -501.09% (higher).

EBIT

31.20 MUSD

YoY

-501.09%

Last updated:

In 2026, Biostem Technologies's EBIT was 31.20 M USD, a -501.09% increase from the -7.78 M USD EBIT recorded in the previous year.

The Biostem Technologies EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2016
-3.13 base
Jan 1, 2017
-4.83 base
Jan 1, 2020
-1.84 base
Jan 1, 2021
-1.43 base
Jan 1, 2023
-7.78 base
Jan 1, 2024
31.20 base
Jan 1, 2025 (e)
40.28 base
Jan 1, 2026 (e)
71.58 base
YEAREBIT (M USD)
2026 est 71.58
2025 est 40.28
2024 31.20
2023 -7.78
2021 -1.43
2020 -1.84
2017 -4.83
2016 -3.13
2015 -2.36
2012 -0.24
2011 -0.53
2010 -0.39
1999 -7.94
1998 -0.87
Access this data via the Eulerpool API

Biostem Technologies Revenue

Biostem Technologies Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2016
620,000.00 USD
-3.13 M USD
-3.20 M USD
Jan 1, 2017
330,000.00 USD
-4.83 M USD
-4.84 M USD
Jan 1, 2020
2.52 M USD
-1.84 M USD
-2.39 M USD
Jan 1, 2021
4.34 M USD
-1.43 M USD
-1.37 M USD
Jan 1, 2023
16.69 M USD
-7.78 M USD
-8.48 M USD
Jan 1, 2024
301.83 M USD
31.20 M USD
31.88 M USD
Jan 1, 2025 (e)
232.87 M USD
40.28 M USD
5.75 M USD
Jan 1, 2026 (e)
276.73 M USD
71.58 M USD
6.42 M USD

Biostem Technologies Margins

Biostem Technologies stock margins

The Biostem Technologies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biostem Technologies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biostem Technologies.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2016
35.48 %
-504.84 %
-516.13 %
Jan 1, 2017
54.55 %
-1,463.64 %
-1,466.67 %
Jan 1, 2020
49.60 %
-73.02 %
-94.84 %
Jan 1, 2021
64.98 %
-32.95 %
-31.57 %
Jan 1, 2023
92.45 %
-46.62 %
-50.84 %
Jan 1, 2024
95.45 %
10.34 %
10.56 %
Jan 1, 2025 (e)
95.45 %
17.30 %
2.47 %
Jan 1, 2026 (e)
95.45 %
25.86 %
2.32 %

Biostem Technologies Stock analysis

What does Biostem Technologies do? Biostem Technologies Inc is a US company specializing in regenerative medicine. It was founded in 2007 and is based in Clearwater, Florida. Biostem Technologies is listed on the OTCQB Stock Exchange and offers a wide range of products in the field of regenerative medicine. The company's business model primarily involves advancing growth in the field of regenerative medicine through the development and marketing of new products and technologies. They focus on the production of stem cells that can be used in the regeneration of damaged tissues and organs. They also offer research and development of stem cell therapies, manufacturing of stem cell products, and related services. Biostem Technologies places emphasis on processing umbilical cord blood stem cells, collaborating with medical facilities to collect and isolate these cells for preservation. The company has also developed products such as BioStem Serum and BioStem Gel, made from stem cells and used in regeneration and wound healing. They have developed technologies for regenerating damaged tissues and organs, including a technology for regenerating muscle and adipose tissue through stem cell injection. Clinical studies have shown promising results with this technology. Biostem Technologies has partnerships with other companies and institutes in the field of regenerative medicine, including working with the National Institute of Neurological Disorders and Stroke to develop a new therapy for multiple sclerosis. They also provide consulting services to assist other companies in developing regenerative products and services. In conclusion, Biostem Technologies is a leading company in the field of regenerative medicine and stem cell therapies, offering a range of products and services. They also provide important technologies for tissue regeneration, positioning them as a key player in the field of regenerative medicine. Biostem Technologies is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Biostem Technologies's EBIT

Biostem Technologies's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Biostem Technologies's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Biostem Technologies's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Biostem Technologies’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Biostem Technologies stock

EBIT of Biostem Technologies is 31.20 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Biostem Technologies

All Key Metrics — Biostem Technologies